Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Praticien-chercheur
16 articles scientifiques publiés — formation continue solide
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The American journal of sports medicine · 2014
Background: The effect of platelet-rich plasma (PRP) on chondrocytes has been studied in cell and tissue culture, but considerably less attention has been given to the effect of PRP on synoviocytes. Fibroblast-like synoviocytes (FLS) compose 80% of the normal human synovium and produce cytokines and matrix metalloproteinases that can mediate cartilage catabolism. Purpose: To compare the effects of leukocyte-rich PRP (LR-PRP), leukocyte-poor PRP (LP-PRP), red blood cell (RBC) concentrate, and platelet-poor plasma (PPP) on human FLS to determine whether leukocyte and erythrocyte concentrations of PRP formulations differentially affect the production of inflammatory mediators. Study Design: Controlled laboratory study. Methods: Peripheral blood was obtained from 4 donors and processed to create LR-PRP, LP-PRP, RBCs, and PPP. Human synoviocytes were cultured for 96 hours with the respective experimental conditions using standard laboratory conditions. Cell viability and inflammatory mediator production were then evaluated. Results: Treatment with LR-PRP resulted in significantly greater synoviocyte death (4.9% ± 3.1%) compared with LP-PRP (0.72% ± 0.70%; P = .035), phosphate-buffered saline (PBS) (0.39% ± 0.27%; P = .018), and PPP (0.26% ± 0.30%; P = .013). Synoviocytes treated with RBC concentrate demonstrated significantly greater cell death (12.5% ± 6.9%) compared with PBS ( P < .001), PPP ( P < .001), LP-PRP ( P < .001), and LR-PRP (4.9% ± 3.1%; P < .001). Interleukin (IL)–1β content was significantly higher in cultures treated with LR-PRP (1.53 ± 0.86 pg/mL) compared with those treated with PBS (0.22 ± 0.295 pg/mL; P < .001), PPP (0.11 ± 0.179 pg/mL; P < .001), and RBCs (0.64 ± 0.58 pg/mL; P = .001). IL-6 content was also higher with LR-PRP (32,097.82 ± 22,844.300 pg/mL) treatment in all other groups ( P < .001). Tumor necrosis factor–α levels were greatest in LP-PRP (9.97 ± 3.110 pg/mL), and this was significantly greater compared with all other culture conditions ( P < .001). Interferon-γ levels were greatest in RBCs (64.34 ± 22.987 pg/mL) and significantly greater than all other culture conditions ( P < .001). Conclusion: Treatment of synovial cells with LR-PRP and RBCs resulted in significant cell death and proinflammatory mediator production. Clinical Relevance: Clinicians should consider using leukocyte-poor, RBC-free formulations of PRP when administering intra-articularly.
Bone & joint research · 2014
BackgroundResveratrol is a polyphenolic compound commonly found in the skins of red grapes. Sirtuin 1 (SIRT1) is a human gene that is activated by resveratrol and has been shown to promote longevity and boost mitochondrial metabolism. We examined the effect of resveratrol on normal and osteoarthritic (OA) human chondrocytes.MethodsNormal and OA chondrocytes were incubated with various concentrations of resveratrol (1 µM, 10 µM, 25 µM and 50 µM) and cultured for 24, 48 or 72 hours or for six weeks. Cell proliferation, gene expression, and senescence were evaluated.ResultsSIRT1 was significantly upregulated in normal chondrocytes with resveratrol concentrations of 25 µM and 50 µM on both two- (2D) (both p = 0.001) and three-dimensional (3D) cultures (p = 0.008 and 0.001, respectively). It was significantly upregulated in OA chondrocytes treated with 10 µM, 25 µM and 50 µM resveratrol on 2D cultures (p = 0.036, 0.002 and 0.001, respectively) and at 50 µM concentration on 3D cultures (p = 0.001). At 72 hours, the expression of collagen (COL)-10, aggrecan (AGG), and runt-related transcription factor 2 (RUNX2) was significantly greater in both 25 µM (p = 0.011, 0.006 and 0.015, respectively) and 50 µM (p = 0.019, 0.004 and 0.002, respectively) resveratrol-treated normal chondrocyte cultures. In OA chondrocytes, expression of COL10 and RUNX2 was significantly greater in 25 µM (p = 0.004 and 0.024) and 50 µM (p = 0.004 and 0.019) cultures at 72 hours on 3D cultures.ConclusionsAt concentrations of 25 µM and/or 50 µM, resveratrol treatment significantly upregulates SIRT1 gene expression in normal and osteoarthritic chondrocytes. Resveratrol induces chondrocytes into a hypertrophic state through upregulation of COL1, COL10, and RUNX2. Cite this article: Bone Joint Res 2014;3:51–9.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The American journal of sports medicine · 2014 · Journal Article
Braun HJ, Kim HJ, Chu CR, Dragoo JL
Bone & joint research · 2014 · Journal Article
Kim HJ, Braun HJ, Dragoo JL
Bone · 2012 · Journal Article
Braun HJ, Gold GE
Imaging in medicine · 2011 · Journal Article
Braun HJ, Gold GE
MMW, Munchener medizinische Wochenschrift · 1983 · Journal Article
Seinfeld H, Braun HD
Die Medizinische Welt · 1982 · Journal Article
Rau R, Konstantinidou D, Braun HD
Padiatrie und Grenzgebiete · 1981 · Journal Article
Braun HS, Ender I, Ender A
MMW, Munchener medizinische Wochenschrift · 1978 · English Abstract
Schlemmer H, Braun HD
Medizinische Klinik · 1965 · Journal Article
Braun H, Jacob KO
Munchener medizinische Wochenschrift (1950) · 1965 · Journal Article
VORLAENDER KO, BRAUN HJ, GRENZMANN M
Munchener medizinische Wochenschrift (1950) · 1959 · Journal Article
VORLAENDER KO, FRITZ KW, BRAUN HJ
Archiv fur Ohren-, Nasen- und Kehlkopfheilkunde · 1954 · Journal Article
MOSER F, BRAUN H
Fortschritte auf dem Gebiete der Rontgenstrahlen · 1952 · Journal Article
BRAUN H
Medizinische Monatsschrift · 1953 · Journal Article
BRAUN H
Drug metabolism and disposition: the biological fate of chemicals · 2016 · Journal Article
Aouri M, Barcelo C, Ternon B, Cavassini M, et al.
European radiology · 2019 · Comparative Study
Braun H, Geniez C, Degboe Y, Constantin A, et al.